Biogen Overview

  • Year Founded
  • 1978

Year Founded

  • Status
  • Public

  • Employees
  • 9,784

Employees

  • Stock Symbol
  • BIIB

Stock Symbol

  • Investments
  • 68

  • Share Price
  • $124.76
  • (As of Monday Closing)

Biogen General Information

Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Contact Information

Website
www.biogen.com
Formerly Known As
Biogen Idec, Idec Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 225 Binney Street
  • Cambridge, MA 02142
  • United States
+1 (781)
Primary Industry
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 225 Binney Street
  • Cambridge, MA 02142
  • United States
+1 (781)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biogen Stock Performance

As of 23-Jun-2025, Biogen’s stock price is $124.76. Its current market cap is $18.3B with 147M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$124.76 $127.04 $110.03 - $238.00 $18.3B 147M 1.67M $10.16

Biogen Financials Summary

As of 31-Mar-2025, Biogen has a trailing 12-month revenue of $9.8B.

In Thousands,
USD
TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 24,285,246 27,235,101 42,918,484 41,591,069
Revenue 9,816,400 9,675,900 9,835,600 10,173,400
EBITDA 2,628,300 2,761,900 1,762,000 4,267,500
Net Income 1,479,300 1,632,200 1,161,100 3,046,900
Total Assets 28,033,100 28,049,300 26,844,800 24,554,100
Total Debt 6,621,200 6,630,300 7,338,200 6,614,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biogen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biogen‘s full profile, request access.

Request a free trial

Biogen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer dru
Biotechnology
Cambridge, MA
9,784 As of 2025

Pasadena, CA
 

Mechelen, Belgium
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biogen Competitors (32)

One of Biogen’s 32 competitors is Arrowhead Pharmaceuticals, a Corporation company based in Pasadena, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arrowhead Pharmaceuticals Corporation Pasadena, CA
Galapagos (Biotechnology) Formerly VC-backed Mechelen, Belgium
AbbVie Corporation North Chicago, IL
Moderna Formerly VC-backed Cambridge, MA
CureVac Formerly VC-backed Tubingen, Germany
You’re viewing 5 of 32 competitors. Get the full list »

Biogen Patents

Biogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240139487-A1 Implantable cranial medical device Pending 01-Nov-2022
AU-2023365490-A1 Compositions and methods for treating retinitis pigmentosa Pending 21-Oct-2022
EP-4562018-A1 Compounds for treating huntington's disease Pending 29-Jul-2022
EP-4558481-A1 Emopamil-binding protein inhibitors and uses thereof Pending 22-Jul-2022
AU-2023308205-A1 Emopamil-binding protein inhibitors and uses thereof Pending 15-Jul-2022 C07D405/12
To view Biogen’s complete patent history, request access »

Biogen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biogen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Biogen‘s full profile, request access.

Request a free trial

Biogen Investments & Acquisitions (68)

Biogen’s most recent deal was a Later Stage VC with Autobahn Therapeutics for . The deal was made on 24-Jul-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Autobahn Therapeutics 24-Jul-2024 Later Stage VC Biotechnology
HI-Bio 02-Jul-2024 Merger/Acquisition Biotechnology
Reata Pharmaceuticals 26-Sep-2023 Merger/Acquisition Drug Discovery
Autobahn Therapeutics 08-Sep-2022 Later Stage VC Biotechnology
Atalanta Therapeutics 11-Jan-2021 Early Stage VC Drug Discovery
You’re viewing 5 of 68 investments and acquisitions. Get the full list »

Biogen ESG

Risk Overview

Risk Rating

Updated April, 18, 2025

20.35 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,673

Rank

Percentile

Pharmaceuticals

Industry

of 844

Rank

Percentile

Biotechnology

Subindustry

of 366

Rank

Percentile

To view Biogen’s complete esg history, request access »

Biogen Exits (35)

Biogen’s most recent exit was on 01-Nov-2018 from Samsung Bioepis. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Samsung Bioepis 01-Nov-2018 Completed
Ionis Pharmaceuticals 11-Jun-2018 Completed
Solid Biosciences 30-Mar-2017 Completed
  • 8 buyers
Ionis Pharmaceuticals 03-Aug-2016 Completed
Yumanity Therapeutics 18-Feb-2016 Early Stage VC Completed
  • 7 buyers
You’re viewing 5 of 35 exits. Get the full list »

Biogen Affiliates

Subsidiaries (3)

Name Industry Location Year Founded
AliveGen USA Thousand Oaks, CA 2014
TYSABRI NC 2004
Biogen (Biosimilar Unit) MA

Biogen FAQs

  • When was Biogen founded?

    Biogen was founded in 1978.

  • Where is Biogen headquartered?

    Biogen is headquartered in Cambridge, MA.

  • What is the size of Biogen?

    Biogen has 9,784 total employees.

  • What industry is Biogen in?

    Biogen’s primary industry is Biotechnology.

  • Is Biogen a private or public company?

    Biogen is a Public company.

  • What is Biogen’s stock symbol?

    The ticker symbol for Biogen is BIIB.

  • What is the current stock price of Biogen?

    As of 23-Jun-2025 the stock price of Biogen is $124.76.

  • What is the current market cap of Biogen?

    The current market capitalization of Biogen is $18.3B.

  • What is Biogen’s current revenue?

    The trailing twelve month revenue for Biogen is $9.8B.

  • Who are Biogen’s competitors?

    Arrowhead Pharmaceuticals, Galapagos (Biotechnology), AbbVie, Moderna, and CureVac are some of the 32 competitors of Biogen.

  • What is Biogen’s annual earnings per share (EPS)?

    Biogen’s EPS for 12 months was $10.16.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »